Development of the CpG Adjuvant 1018: A Case Study (Q40549653)

21 September 2017

1 reference

title

Development of the CpG Adjuvant 1018: A Case Study (English)

1 reference

21 September 2017

John D Campbell

1

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 January 2017

1 reference

Methods in Molecular Biology

21 September 2017

published in

1 reference

21 September 2017

volume

1494

1 reference

21 September 2017

page(s)

15-27

1 reference

Vaccination greatly reduces disease, disability, death and inequity worldwide

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Recent advances of vaccine adjuvants for infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Vaccine Adjuvants: Putting Innate Immunity to Work

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Pathogen recognition and inflammatory signaling in innate immune defenses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Mechanism and function of a newly identified CpG DNA motif in human primary B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Phosphorothioate oligonucleotides: effectiveness and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Immunostimulatory DNA as a vaccine adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Hepatitis B virus: where do we stand and what is the next step for eradication?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Immunogenicity of combined hepatitis A and B vaccine in elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Vaccination in the elderly: an immunological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Persistence of specific antibodies after hepatitis B vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

The use of vaccines in renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-6445-1_2

10.1007/978-1-4939-6445-1_2

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference